Ablynx has established partnerships around specific products and Nanobody drug discovery collaborations with leading pharmaceutical companies, many of which have engaged into multiple agreements. We are actively looking for new partnerships with companies who are interested in in-licensing pre-clinical or clinical stage programmes, or who are interested in developing Nanobody-based therapeutics in areas where the Nanobody technology offers competitive advantages over full-length antibodies and/or other antibody fragments or scaffolds:
- Broad target applicability, including challenging targets such as GPCRs and ion channels
- Formatting flexibility, allowing a mix and match approach to find the best epitope or target combinations
- Choice of half-life
- Robustness allowing for alternative delivery methods such as nebulisation
- Excellent manufacturing in a range of hosts and excellent biophysical properties
Nanobody Drug discovery collaborations
Ablynx applies different approaches to Nanobody drug discovery collaborations, including fully funded target collaborations, co-discovery/co-development collaborations, IND generation collaborations and strategic partnerships. We also have the opportunity to leverage existing assets to kick-start a collaboration, for example in the area of multi-specifics. Please contact Gosia Ciesiolka or Cedric Ververken for more information.
Partnering of proprietary programmes
During product development, Ablynx seeks partnerships with companies that are interested in in-licensing a programme or further developing a programme in a co-development and co-commercialisation partnership. Please contact Gosia Ciesiolka or Cedric Ververken for more information on the specific partnering objectives for the on-going programmes.